Exclusive Summary

• Backed by top-tier US-FDA and UK-MHRA GMP certifications and active US registration, offering an impeccable quality profile that heavily attracts clients in both highly regulated and emerging markets.
• The 400mg/800mg dosages precisely target the massive global demand for genital herpes and shingles therapies, addressing a huge patient population with zero patent risks.
• As a first-line antiviral gold standard on the WHO Essential Medicines List, its US approval status enables fast-track commercialization in multiple countries via regulatory reliance pathways.
• Supported by the robust, large-scale manufacturing capabilities, ensuring long-term supply chain stability and a highly competitive cost advantage over Western originators and generic peers.